Pertuzumab and trastuzumab are monoclonal antibody inhibitors targeting human epidermal growth factor receptor 2 (HER-2) and are increasingly being utilised in the management of HER2-positive breast cancer, having been demonstrated to improve progression-free survival in conjunction with docetaxel. We present a rare presentation of a lichenoid drug eruption, in an annular atrophic variant, in a 35-year-old woman after initiation of HER2-inhibitor (pertuzumab and trastuzumab) therapy for metastatic breast cancer.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/ajd.13501 | DOI Listing |
Publication Analysis
Top Keywords
annular atrophic
8
pertuzumab trastuzumab
8
breast cancer
8
atrophic lichen
4
lichen planus
4
planus induced
4
induced anti-her2
4
anti-her2 antibodies
4
antibodies pertuzumab
4
trastuzumab monoclonal
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!